IASLC胸部腫瘍学（第２版） IASLC Thoracic Oncology E-Book（2）

著者名：Pass MD, Harvey/Ball MD, FRANZCR, David/Scagliotti MD, PhD, Giorgio

Elsevier（2017/04/21発売）

• 言語：ENG
• ISBN：9780323523578
• eISBN：9780323527842

Description

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today's best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.- Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy.- Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer.- Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer.- Features a new full-color design throughout, as well as updated diagnostic algorithms.- Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.

Table of Contents

Section 1: Lung Cancer Control and Epidemiology1. Classical Epidemiology2. Tobacco Control and Primary Prevention3. Tobacco Cessation 　4. Non-Smoking Related Lung Cancer5. Gender-Related Differences in Lung Cancer6. Genetic Susceptibility to Lung Cancer7. Early Detection and Radiologic Screening8. Preclinical Biomarkers for The Early Detection of Lung Cancer9. Chemoprevention of Lung Cancer: Present and Developing TechnologiesSection 2: Lung Cancer Molecular Carcinogenesis10. Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies11. Mutational Events in Lung Cancer: Present and Developing Technologies12. Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies13. Stem Cells and Lung Cancer: In Vitro and In Vivo Studies14. Microenvironment and Lung Cancer　　15. MicroRNAs as Biomarkers for Lung CancerSection 3: Immunology16. Humoral and Cellular Immune Dysregulation and Lung CancerSection 4: Pathology17. Classic Anatomic Pathology and Lung Cancer18. Molecular Testing and Lung Cancer19. Management of the Small Biopsy in the Molecular Er　　Section 5: Clinical and Radiologic Presentation of Lung Cancer20. Clinical Presentation　　21. Conventional Imaging Lung Cancer22. PET Imaging of Lung CancerSection 6: Diagnosis and Staging of Lung Cancer23. Diagnostic Work-Up of Suspected Lung Cancer24. Surgical Staging of the Mediastinum including Mediastinoscopy and Thoracoscopy, Preoperative and Intraoperative25. The 8th Edition of the Tumor, Node and Metastasis Classification of Lung CancerSection 7: Surgical Management of Lung Cancer26. Preoperative Functional Evaluation of the Surgical Candidate　　27. Results of Video Assisted Techniques for Resection of Lung Cancer　　28. Results of Robotic Techniques for Resection of Lung Cancer29. Extent of Surgical Resection for Stage I and II Lung Cancer　　30. Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors　　31. Extended Resections for Lung Cancer: Broncho/Vascular Sleeve Resections32. Multiple Nodules: Management of the Patient with Synchronous or Metachronous Lung Cancers33. Surgical Management of the Marginally Resectable PatientSection 8: Radiotherapeutic Management of Lung Cancer34. Technical Requirements for Lung Cancer Radiotherapy35. Radiobiology of Lung Cancer36. Patient Selection for Radiotherapy　37. Stage I Non-Small Cell Lung Cancer and Oligometastatic Disease38. Ablation Options for Localized Lung Cancer39. Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, including Combined Modality40. Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation41. Palliative Radiotherapy for Lung Cancer: Locoregional and Metastatic42. Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, Heart43. Treatment-Related Neurotoxicity, Medical and Radiation TherapySection 9: Chemotherapy and Targeted Agents for Lung Cancer44. Front-Line Systemic Options in Non-Small Cell Lung Cancer　　45. Systemic Options in Second Line and Beyond46. Maintenance Therapy in NSCLC47. Pharmacogenomics and Lung Cancer48. New Targetable Pathways in Lung Cancer49. Management of Toxicities of Targeted Therapies50. Immunotherapy and Lung Cancer51. Systemic Therapy in Early-Stage NSCLC52. Treatment of Small-Cell Lung CancerSection 10: Other Thoracic Malignancies53. Malignant Mesothelioma54. Mediastinal Tumors55. Neuroendocrine Tumors of the Lung Other than SCLC56. Thymic Cancer/ThymomaSection 11: Symptom Management and Complications57. Lung Cancer Emergencies58. Role of Palliative Care in Lung CancerSection 12: Clinical Trials59. Methodology of Clinical Trials in Lung Cancer　60. How to Promote and Organize Clinical Research in Lung CancerSection 13: Thoracic Oncology Advocacy61. Role of Advocacy Groups in Lung Cancer62.